AstraZeneca's Investigational Cancer Drug Shows First-Line Benefit In Combination With Widely Cancer Medicines

Zinger Key Points

Camizestrant plus a CDK4/6 inhibitor showed significant improvement in progression-free survival in certain form of advanced breast cancer.
The camizestrant combination showed a trend toward improved second disease progression, with safety profile consistent with known treatment.
Our government trade tracker caught Pelosi’s 169% AI winner. Discover how to track all 535 Congress member stock trades today.

On Wednesday, AstraZeneca Plc AZN released high-level results from a planned interim analysis of the SERENA-6 Phase 3 trial.

SERENA-6 is evaluating the efficacy and safety of camizestrant in combination with a CDK4/6 inhibitor (palbociclib, ribociclib or abemaciclib) versus treatment with an AI (anastrozole or letrozole) in combination with a CDK4/6 inhibitor for HR-positive, HER2-negative advanced breast cancer whose tumors have an emergent ESR1 mutation.

Also Read: Amid Mounting Pressure In China, AstraZeneca Buys FibroGen’s Chinese Unit For $160 Million

The data showed that the camizestrant combination regime demonstrated a statistically significant and clinically meaningful improvement in the progression-free survival (PFS) endpoint.

The key secondary endpoints of time-to-second disease progression (PFS2) and overall survival (OS) were immature at the time of this interim analysis.

However, the camizestrant combination demonstrated a trend toward improvement in PFS2. The safety profile of camizestrant in combination with palbociclib, ribociclib or abemaciclib in SERENA-6 was consistent with the known safety profile of each medicine.

No new safety concerns were identified, and discontinuations were very low and similar in both arms.

Earlier this month, AstraZeneca shared results from a post-hoc exploratory subgroup analysis from the NIAGARA Phase 3 trial.

The study showed that Imfinzi (durvalumab), administered perioperatively in combination with neoadjuvant (before surgery) chemotherapy, demonstrated improvements in event-free survival and overall survival versus neoadjuvant chemotherapy with radical cystectomy alone in patients with or without a pathologic complete response in muscle-invasive bladder cancer.

Price Action: AZN stock is up 0.68% at $75.93 at the last check on Wednesday.

Read Next